marked.bio

anti-PD-L1 antibody · antibody

adebrelimab

15 active trials across 6 of our biomarkers, targeting PD-L1. Not approved for any biomarker on marked.bio yet.

Also known as SHR-1316.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
KRAS G12C 6 6 Phase 3
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 4 6 Phase 2
KRAS G12D 4 4 Phase 2/3
Claudin 18.2 expression 2 2 Phase 2
ALK fusion 1 1 Phase 1/2
MSI-H / dMMR 1 1 Phase 2

Sponsors

Industry sponsors leading active biomarker-selected trials of adebrelimab.

  1. Jiangsu Hengrui 4
  2. Hansoh Pharma 3

Trials

15 of 17 trials shown

  1. A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

    Not yet recruiting Phase 3 Hansoh Pharma Started 2026Primary completion 2030-05 NCT07822542

    HS-10370adebrelimabcisplatincarboplatinpemetrexedtislelizumab

    Documentation of the presence of a KRAS G12C mutation

    KRAS G12CCarcinoma, Non-Small-Cell Lung

  2. A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

    Not yet recruiting Phase 2/3 Jiangsu Hengrui Started 2024Primary completion 2028-10 NCT06335355

    adebrelimabpemetrexedcarboplatincamrelizumab

    Participants must have tumors with STK11 or KEAP1 or KRAS mutations.

    KRAS G12CKRAS G12DStatus may be outdated, last updated 2024-03-28Non-squamous Non-small Cell Lung Cancer

  3. A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer

    Not yet recruiting Phase 1/2 Zhejiang University Started 2026Primary completion 2028-08 NCT07736612

    HRS-2329 TabletNimotuzumabHS-20093adebrelimab

    RAS mutation or amplification detected in tumor tissue or blood (by RAS testing).

    KRAS G12CKRAS G12DPancreatic Cancer, RAS Mutations or Amplifications

  4. An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors

    Recruiting Phase 1/2 Jiangsu Hengrui Started 2026Primary completion 2028-12 NCT07806058

    adebrelimabHRS-7172 + AG;HRS-4642

    …ocally advanced or metastatic pancreatic cancer confirmed by histology and cytology, with RAS mutation/amplification detected by tissue or blood genetic testing.

    KRAS G12CKRAS G12DPancreatic Cancer

  5. Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma

    Not yet recruiting Phase 1/2 Sun Yat-sen University Started 2026Primary completion 2030-05 NCT07615283

    adebrelimab

    Systemic anaplastic large cell lymphoma (ALK+ and ALK-);

    ALK fusionRelapsed or Refractory Peripheral T Cell Lymphoma, NKTCL

  6. Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer

    Recruiting Phase 2 Peking Union Medical College Hospital Started 2026Primary completion 2027-04 NCT07670273

    trastuzumab rezetecanadebrelimablenvatinib

    HER2 positive (IHC 3+ or IHC 2+ and FISH detects HER2/CEP17 ≥ 2.0), HER2 low expression (IHC 2+/FISH- or IHC 1+);

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Biliary Tract Neoplasms Immunotherapy

  7. Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer

    Recruiting Phase 2 Peking Union Medical College Hospital Started 2026Primary completion 2027-04 NCT07704177

    trastuzumab rezetecanadebrelimablenvatinib

    HER2 positive (IHC 3+ or IHC 2+ and FISH detects HER2/CEP17 ≥ 2.0), HER2 low expression (IHC 2+/FISH- or IHC 1+)

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Biliary Tract Neoplasms Immunotherapy

  8. Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer

    Not yet recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences Started 2026Primary completion 2028-10 NCT07317778

    trastuzumab rezetecanadebrelimabTaxane Chemotherapycyclophosphamide

    HR positive/HER2 low expression(defined as HER2 IHC 1+/2+, FISH negative);

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer

  9. Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 Study

    Not yet recruiting Phase 2 Shanghai Zhongshan Hospital Started 2026Primary completion 2030-06 NCT07266025

    adebrelimabXELOXSHR-8068

    dMMR confirmed by IHC or MSI-H confirmed by PCR

    MSI-H / dMMRGastric Adenocarcinoma, Gastroesophageal Adenocarcinoma, Mismatch Repair Deficient or MSI-High Solid Tumors, Immunotherapy

  10. Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

    Not yet recruiting Phase 2 China Medical University Started 2025Primary completion 2029-08 NCT06881017

    trastuzumabadebrelimabapatinibS-1capecitabineoxaliplatinzolbetuximab FDA EUtrastuzumab rezetecanSHR-A1904SHR-1701

    Archival or fresh tumor tissue sample available for biomarker testing (HER2, CLDN18.2, and PD-L1 expression);

    Claudin 18.2 expressionGastric Cancer, HER2 + Gastric Cancer, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, PD-L1 Positive

  11. A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

    Active, not recruiting Phase 1/2 Jiangsu Hengrui Started 2024Primary completion 2025-12 NCT06385678

    HRS-4642adebrelimabSHR-9839pemetrexedcisplatincarboplatincetuximab

    With unresectable locally advanced or metastatic solid tumors harbouring with KRAS G12D mutation confirmed by central laboratory testing.

    KRAS G12DAdvanced KRAS G12D Mutant Solid Tumors

  12. SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer

    Recruiting Phase 2 Shengjing Hospital Started 2024Primary completion 2026-02 NCT06340230

    trastuzumab rezetecanadebrelimab

    Histologically confirmed to be HR+/HER2-Low invasive breast cancer

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)HR Positive/HER2 Low Breast Cancer

  13. A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

    Not yet recruiting Phase 1 Hansoh Pharma Started 2025Primary completion 2028-12 NCT06963502

    HS-10370HS-20117adebrelimabcapecitabineoxaliplatinleucovorinfluorouracilirinotecanHS-20093cisplatincarboplatin

    Documentation of the presence of a KRAS G12C mutation

    KRAS G12CAdvanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer

  14. A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

    Not yet recruiting Phase 1 Hansoh Pharma Started 2024Primary completion 2026-10 NCT06594874

    HS-10370adebrelimabcisplatincarboplatinpemetrexed

    Documentation of the presence of a KRAS G12C mutation

    KRAS G12CStatus may be outdated, last updated 2024-09-19Non-Small Cell Lung Cancer, Advanced Solid Tumors

  15. SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor

    Recruiting Phase 1 Jiangsu Hengrui Started 2024Primary completion 2027-12 NCT06350006

    SHR-A1904adebrelimabCAPOX

    6. positive CLDN18.2 expression in tumor tissue;

    Claudin 18.2 expressionCLDN18.2-positive Advanced Solid Tumor